Methods of treating hematologic cancers
AssigneeMayo Foundation for Medical Education and Research
InventorsNeil E. Kay, Tait D. Shanafelt
Life of this patent
Estimating the term…
Abstract
This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are described.
Claims9
A method of treating a hematologic cancer in a subject having a hematologic cancer comprising the steps of:
- (a) administering to the subject an effective amount of epigallocatechin gallate (EGCG), or a pharmaceutically acceptable salt, ester, or salt of an ester thereof;
- and
- (b) administering to the subject an effective amount of fludarabine, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof, and chlorambucil, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof.
A method of treating chronic lymphocytic leukemia in a subject having a hematologic cancer, the method comprising administering to the subject a composition comprising EGCG, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof, flurdarabine, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof, and chlorambucil, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof.
Dependencies are inferred from the claim text.